,4,5 These receptors are intensively investigated for their clinical activity in combination with PD1/PD-L1 antagonist with the aim to demonstrate a potential synergistic effect and to improve immunotherapy efficacy in patients with advanced NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.